Skip to main content

CERS

Stock
Health Care
Medical Devices

Performance overview

CERS Price
Price Chart

Forward-looking statistics

Beta
1.34
Risk
69.04%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Company info

SectorHealth Care
IndustryMedical Devices
Employees343
Market cap$329.1M

Fundamentals

Enterprise value$288.8M
Revenue$185.1M
Revenue per employee
Profit margin-10.23%
Debt to equity176.82

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.10
Dividend per share
Revenue per share$1.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-4.7
Credit+9.4
Liquidity+2.1
Inflation-7.4
Commodities-1.7
Interest Rates-3.8

Valuation

Dividend yield0.00%
PEG Ratio-22.00
Price to sales1.59
P/E Ratio-22.00
Enterprise Value to Revenue1.56
Price to book5.31

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

Cerus (CERS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.

Zacks Investment Research (May 1, 2025)
Cerus Stock Gains As Q2 Earnings Match Expectations, Raises FY21 Sales Guidance

Cerus Corporation (NASDAQ: CERS) reported second-quarter sales of $37.8 million, +41% Y/Y in line with the consensus. Product revenue reached $31.5 million, compared to $21.5 million a year ago, benefited from increased demand for INTERCEPT platelet products in the U.S.

Benzinga (August 4, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free